Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,217Revenue (TTM) $M0.6Net Margin (%)-47,062.3Altman Z-Score9.3
Enterprise Value $M4,027EPS (TTM) $-7.3Operating Margin %-44,574.2Piotroski F-Score5
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-47,062.3Higher ROA y-yY
Price/Book25.610-y EBITDA Growth Rate %--Quick Ratio5.4Cash flow > EarningsY
Price/Sales6,1335-y EBITDA Growth Rate %--Current Ratio5.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-87.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-169.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M45.9ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with TSRO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TSRORon Baron 2016-03-31 Buy $32.01 - $52.32
($40.2)
$ 91.99129%New holding2,000
TSRODavid Swensen 2015-12-31 Sold Out -0.08%$40.35 - $52.91
($47.98)
$ 91.9992%Sold Out0
TSRODavid Swensen 2015-09-30 Buy 0.08%$38.97 - $65.8
($54.68)
$ 91.9968%New holding6,238
TSROLeon Cooperman 2015-06-30 Sold Out -0.05%$50.84 - $64.65
($57.38)
$ 91.9960%Sold Out0
TSROLeon Cooperman 2015-03-31 Buy 0.05%$36.62 - $61.41
($47.12)
$ 91.9995%New holding50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TSRO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


TSRO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Hanke Jeffrey H.Executive VP, R&D and CSO 2016-06-30Sell12,500$74.3523.73view
English Edward CVP of Finance & Administration 2016-06-10Sell7,000$40.75125.74view
Weller Harry R10% Owner 2016-03-18Buy1,420,858$35.19161.41view
Viswanathan Ravi10% Owner 2016-03-18Buy1,420,858$35.19161.41view
SANDELL SCOTT D10% Owner 2016-03-18Buy1,420,858$35.19161.41view
MOTT DAVID MDirector, 10% Owner 2016-03-18Buy1,420,858$35.19161.41view
KERINS PATRICK J10% Owner 2016-03-18Buy710,429$35.19161.41view
BASKETT FOREST10% Owner 2016-03-18Buy1,420,858$35.19161.41view
BARRIS PETER J10% Owner 2016-03-18Buy1,420,858$35.19161.41view
BARRETT M JAMES10% Owner 2016-03-18Buy710,429$35.19161.41view

Quarterly/Annual Reports about TSRO:

News about TSRO:

Articles On GuruFocus.com
Major Second Quarter Purchases for Cohen include Tesaro, Pernix Jul 20 2016 
Steven Cohen Hits Another Home Run in Oncology Jul 07 2016 
David Swensen Bets on Antero Resources Mar 10 2016 
David Swensen's Transactions Show Diversity of Portfolio Nov 19 2015 

More From Other Websites
Gilead Has a Problem. These Three Biotechs Could Be the Solution Jul 22 2016
TESARO to Announce Second-Quarter 2016 Financial Results on August 4, 2016 Jul 21 2016
Coverage initiated on Tesaro by Robert W. Baird Jul 19 2016
10 Stocks That Could Ruin Your Retirement Jul 15 2016
ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial Jul 08 2016
ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial Jul 08 2016
TESARO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Jul 07 2016
TESARO Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters Jul 07 2016
TESARO Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters Jul 07 2016
Steven Cohen Hits Another Home Run in Oncology Jul 07 2016
Buyout target Medivation says cancer drug could be 'best in class' Jul 06 2016
​Tesaro raises $377M in largest local biotech stock offering in the past year Jul 01 2016
Tesaro (TSRO) in Focus: Stock Adds 8.6% in Session Jul 01 2016
TESARO Announces Pricing of Public Offering of Common Stock Jun 30 2016
TESARO Announces Pricing of Public Offering of Common Stock Jun 30 2016
Tesaro Stock Up on Successful Phase III Ovarian Cancer Trial Jun 30 2016
Here’s Why Traders Are Buzzing Around Lions Gate, Stellar Biotechnologies, and Three Other Stocks Jun 30 2016
Protect Gains Into the Holiday Weekend Jun 30 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)